Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

286.21 +2.86 (+1.01%)
Streaming Delayed Price Updated: 10:12 AM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about United Therapeutics Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024
UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
United Therapeutics Stock Skids On Mixed Second-Quarter Results
The company's earnings came in far below expectations, though sales easily beat. 
Via Investor's Business Daily
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
From United Therapeutics Corporation
Via Business Wire
The 3 Best 3D Bioprinting Stocks to Buy Now
These are three of the best 3D bioprinting stocks to buy as the technology begins to hit its stride in the health care sector. 
Via InvestorPlace
Navigating 9 Analyst Ratings For United Therapeutics
Via Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
Via Benzinga
Unveiling 6 Analyst Insights On United Therapeutics
Via Benzinga
Deep Dive Into United Therapeutics Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
From United Therapeutics Corporation
Via Business Wire
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Biotech Arvinas Stock Earns 82 RS Rating
The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82. 
Via Investor's Business Daily
Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag.
Despite its impressive fundamentals, UNITED THERAPEUTICS CORP (NASDAQ:UTHR) remains undervalued. 
Via Chartmill
Denali Therapeutics Stock Gets Technical Rating Upgrade
Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating 
Via Investor's Business Daily
3 Biotech Stocks to Buy Now: Q3 Edition
Biotech stocks to buy can be a strong portfolio addition due to their capability for rapid growth within an evolving industry. 
Via InvestorPlace
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
From United Therapeutics Corporation
Via Business Wire
3 Undervalued Stocks on Track to Double (or More) by 2028
The stock market is on the brink of a multi-year bull market. Consider these undervalued growth stocks to buy that can double or more by 2028. 
Via InvestorPlace
Members of Congress Buy and Sell Stocks. These ETFs Let You Invest Like Democrats or Republicans.
Whether you'd like to invest like Nancy Pelosi or Ted Cruz, you can. But maybe you shouldn't. 
Via The Motley Fool
Topics ETFs
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
Via InvestorPlace
Chart Of The Day: United Therapeutics - Drugs For Chronic Illnesses
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening... 
Via Talk Markets
UroGen Pharma Stock Earns 91 RS Rating
UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier. 
Via Investor's Business Daily
United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
From United Therapeutics Corporation
Via Business Wire
When you look at NASDAQ:UTHR, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Arcellx Stock Earns Relative Strength Rating Upgrade
One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83. 
Via Investor's Business Daily
The 3 Best Medical Device Stocks to Buy in June 2024
Medical devices are at the forefront of the digitalization of medicine. making these the three best medical device stocks to buy. 
Via InvestorPlace
Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87
Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Neurocrine Biosciences Stock Tops Milestone Amid New Drug Plans
Neurocrine Biosciences has long been known for its blockbuster drug Ingrezza. It's diversifying, developing multiple drugs in related areas. 
Via Investor's Business Daily
Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade
On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.